Beyond normalizing prolactin levels, dopamine agonists, considered the first-line treatment for hyperprolactinemia [14], decreased plasma glucose, increased peripheral tissue insulin responsiveness, improved lipid profile, as well as improved anthropometric parameters (the body mass index (BMI), waist circumference and visceral fat content) [1,15,16,17,18,19]. Here, PRL is linked to hyperprolactinemia.